Transition Therapeutics Says FDA Grants Fast Track Designation To ELND005

(RTTNews) - Transition Therapeutics Inc. (TTHI, TTH.TO) Wednesday said the US Food and Drug Administration has granted Fast Track Designation to the development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms in Alzheimer's disease.

The FDA concluded that the development program for ELND005 for the treatment of neuropsychiatric symptoms in Alzheimer's disease meets their criteria for Fast Track Designation.

Transition's licensing partner, Elan Corporation, plc, is responsible for all development and commercialization activities and costs of ELND005.